US Food and Drug Administration. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. J Pain Palliat Care Pharmacother, 2005; 19:83–97.
2.
SinghS, YoonLK, FurbergCD. Long-term risk of cardiovascular events with rosiglitazone: A meta analysis. JAMA, 2007; 298:1189–1195.
3.
MoynihanR. FDA advisory panel calls for suicide warnings over new antidepressants. BMJ, 2004; 328:303.
4.
RayWA, MurrayKT, HallK, ArbogastPG, SteinCM. Azithromycin and the risk of cardiovascular death. N Engl J Med, 2012; 366:1881–1890.
5.
US Food and Drug Administration. Milestones of drug regulation in the United States. http://www.fda.gov/AboutFDA/WhatWeDo/History/FOrgsHistory/CDER/CenterforDrugEvaluationandResearchBrochureandChronology/ucm114463.htm. 2012 July 11.
6.
WysowskiDK, SwartzL. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: The importance of reporting suspected reactions. Arch Intern Med, 2005; 165:1363–1369.
7.
Institute of Medicine. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press, 2012.
8.
JüniP, NarteyL, ReichenbachS, SterchiR, DieppePA, EggerM. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet, 2004; 364:2021–2029.
9.
SaeedM, VillarroelM, ReisnerATet al.Multiparameter Intelligent Monitoring in Intensive Care II (MIMIC-II): A public-access intensive care unit database. Crit Care Med, 2011; 39:952–960.
